All Stories

Former CEO Anne Wojcicki prevails in 23andMe auction, with final $305M bid

Her $305 million offer topped the previous frontrunner, Regeneron, which bid $256 million last month and planned to incorporate the DNA company’s assets in its R&D.

Jun 16, 2025 - 16:20
 0
Former CEO Anne Wojcicki prevails in 23andMe auction, with final $305M bid
Her $305 million offer topped the previous frontrunner, Regeneron, which bid $256 million last month and planned to incorporate the DNA company’s assets in its R&D.
Read More

Tags:

Previous Article

AstraZeneca touts early Ultomiris survival data in children living with rare pos...

Next Article

Gilead lays off 36 people after axing California expansion plan

Related Posts

Odyssey abandons IPO plans in latest sign of tough environment for biotech listings

Odyssey abandons IPO plans in latest sign of tough envi...

Jun 10, 2025  0

'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape

'Not a horse and pony show': At FDA cell and gene round...

Jun 5, 2025  0

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era

BioMarin inks $270M Inozyme buyout, bagging phase 3 pro...

May 16, 2025  0